

# EnBrace *HR/MF*

Advanced Folate Supplement

EnLyte for Women

Small Gel Cap | All-Natural | Root Cause Management

## INNOVATIONS IN WOMEN'S MENTAL & REPRODUCTIVE HEALTH

---

Women of All Ages and their HCPs,  
Desire Treatment Options Designed  
to Address their Unique Mental and  
Reproductive Health Needs  
Effectively and Safely

\*References can be found at the end of this presentation\*



### Clinically Proven Effectiveness for:

- ❖ Depression and Anxiety
- ❖ Including in and Around Pregnancy
- ❖ PMS/PMDD & Menopause
- ❖ High or Low Risk Prenatal Vitamin

EnBrace HR Small Gel Cap

# INGREDIENTS

“EnBrace HR contains the exact clinically recommended vitamin coenzymes, mineral cofactors and omegas needed to normalize uterine and CNS intracellular methylation for normal mental and reproductive clinical outcomes.”

Towny Robinson, CEO JayMac Pharmaceuticals  
Inventor of EnBrace HR

## Diverse Natural Folates: FDA 15mg DFE

L-Methylfolate Magnesium	7mg
Folinic Acid	3.5mg

## B Vitamins in their Bioactive Coenzyme Form

B12 (Adenosylcobalamin)	50mcg
B6 (Pyridoxal-5-Phosphate)	25mcg
B1 (Thiamine Pyrophosphate)	25mcg
B2 (Flavin Adenine Dinucleotide)	25mcg
B3 (Nicotinamide Adenine Dinucleotide)	25mcg
Bioperine (B Vitamin Bioenhancer)	500mcg

## Minerals in their Bioactive Cofactor Form

Magnesium Ascorbate	24mg
Magnesium L-Threonate	1mg
Zinc Ascorbate	1mg
Iron (Ferrous Glycine Cysteinate)	1.5mg

## Phospholipid Form – Brain Ready

PS-Omega-3 (Phosphatidylserine, EPA, DHA)	20mg
---	------

## Absorption Enhancer


Sodium Citrate	10mg
----------------	------

## Energizer


CoQ10	500mcg
-------	--------

# Intracellular Biochemical Root Cause Methylation Chart

EnBrace HR Normalizes All Co-Enzyme/Cofactor Deficiencies and Methylation Disruption, No Matter the Cause and Converts to Normal Mental and Reproductive Health Outcomes Based on Well-Controlled Clinical Trials.



# CLINICAL STUDY OVERVIEW



# THE JOURNAL OF CLINICAL PSYCHIATRY

## 330 ADULT PATIENT RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY

### OBJECTIVE:

This 8-week study was designed to evaluate the efficacy and safety of EnLyte/EnBrace HR as monotherapy in adults with major depressive disorder (MDD) who were also positive for at least 1 methylenetetrahydrofolate reductase (MTHFR) polymorphism associated with depression and further test the hypothesis that EnLyte/EnBrace HR will lower homocysteine in a majority of clinical responding patients.

MAY 2016

Correlation of Clinical Response With Homocysteine Reduction During Therapy With EnLyte/EnBrace HR in Patients With MDD Who Are Positive for MTHFR C677T or A 1298C Polymorphism - Andrew Farah, MD

### 1) Mean MADRS Symptom Score of EnBrace HR Versus Placebo



### 2) 30% Reduction in Homocysteine Levels (Compared to Placebo)

**NO SIDE EFFECT WAS REPORTED AT GREATER RATE  
THAN PLACEBO**


**ONSET OF ACTION: 2 WEEKS**



# EnBrace HR For The Treatment and Prevention of Depression in Women

## Trying to Conceive and During Pregnancy

Marlene P. Freeman, MD et al, Annals of Clinical Psychiatry February 2019



### CONCLUSION

Study results suggest EnBrace HR is a novel and well tolerated intervention with efficacy for the prevention and treatment of depression among women planning pregnancy and who are pregnant.

Figure 1. The aim for Group 1 was to prevent depression relapse, and the aim for Group 2 was to improve depression symptoms, measured through several mood and quality of life questionnaires. Trends shown by group for the primary mood outcome measure, the MADRS (Montgomery-Asberg Depression Rating Scale) in dark blue; for secondary mood measures, the QIDS-SR (Quick Inventory of Depressive Symptomatology-Self Report) in orange and the EPDS (Edinburgh Postnatal Depression Scale) in light blue; and for a quality of life outcome, the QLESQ-SF (Quality of Life Enjoyment and Satisfaction Questionnaire -Short Form) in green. Group 1 experienced no significant changes in any of the four measures, and Group 2 experienced significant improvements in the mood questionnaires but not the quality of life questionnaire. All ANOVAs indicating significance are reported in Table 3.

# PMS

**(Premenstrual Syndrome)**

Mild/Moderate

# Menopause

Cyclic hormonal changes of the menstrual cycle causes fluctuations of serotonin levels leading to adverse symptomology  
– Mayo Clinic –

# PMDD

**(Premenstrual Dysphoric Disorder)**

Severe (DSM-5)



**Tension/Anxiety, Depressed Mood – Irritability/Anger – Appetite Changes – Cravings – Insomnia  
– Social Conflict Withdrawal– Feeling overwhelmed – Hopelessness – Hot Flashes**

## Biochemical Wellness

EnBrace HR normalizes serotonin levels and is an effective, all-natural, safe, root cause monotherapy option or adjunct to SSRIs, oral contraceptives, NSAIDs, diuretics, and/or HRT in the prevention or treatment of PMS/PMDD/MENOPAUSE.

Dietary B Vitamin Intake and Incident of Premenstrual Syndrome. Manson et al. Am J Clin Nutr. 2011

## Clinical Result Example

A 17-year-old on Paxil for PMDD experienced side effects and withdrawal symptoms after discontinuing Paxil. She was hesitant to resume antidepressant medications after presenting again with PMDD depression, and a MADRS of 20. The patient elaborated she was “putting on a happy face”. She was prescribed EnBrace HR and within 4 weeks her MADRS dropped from 20 to 6.

Coenzyme Treatment of Childhood and Adolescent Depression: A Case Series. Farah et al. Clinical Psychiatry Vol 7 #5S3:93 April 2021

**“For the emotional dysregulation of PMS, PMDD, and Menopause we turned first-line to the natural, broad spectrum B vitamin coenzymes and mineral cofactor agent, EnBrace HR. This product has provided safe and effective relief for countless patients with female hormonal fluctuations or deficiency”**

Andrew Farah, MD

Attending Psychiatrist, Novant Health System, Winston-Salem, NC  
Medical Director of Strategic Mental Health Interventions

**Provides the most diverse combination of folates and methylation vitamin coenzymes and mineral cofactors for maximum prevention of NTDs and other birth defects in low or high-risk pregnancies.**

---

**An optimal serum folate level for birth defect prevention should be reached 4 weeks prior to conception, 50% of pregnancies are unplanned.**

---

### **Mechanism of Cellular Action**

Normalize impaired cellular “homocysteine/methionine” metabolism disorders that can lead to placental inflammation, impaired fetal perfusion, impaired nucleotide and DNA synthesis and faulty epigenetic expression.

## **To Prevent or Reduce Risk For:**

---

- ❖ All Neural Tube Defects
- ❖ Congenital Heart & Kidney Disorders
- ❖ Down Syndrome
- ❖ ADHD
- ❖ Autism Spectrum Disorders
- ❖ Orofacial Clefts
- ❖ Drug Related Birth Defects
- ❖ Pregnancy Complications
- ❖ Congenital Structural Malformation


# EnBrace HR Helps Eliminate the Risk for Adverse Pregnancy Outcomes, NTDs, and Other Birth Defects Associated with the effects of MTHFR Gene Variant

MTHFR gene variants prevent the production of the enzyme that converts folate to methylfolate leading to high homocysteine and low neurotransmitter production causing negative reproductive and CNS outcomes.

- 60%** of women have the heterozygous form of MTHFR gene variant
- 25%** of women have the homozygous form of MTHFR gene variant
- 50%** of folate related NTDs and other birth defects are linked to MTHFR
- 85%** of depressed and addicted women have an MTHFR gene variant

## MTHFR Polymorphisms are Documented Risk Factors for these Adverse Pregnancy Outcomes:

- Miscarriage
- Perinatal/ Post-Partum Depression
- Pre-Term Delivery
- Low Birth Weight
- Pre-Eclampsia
- Placental Inflammation
- Impaired Fetal Perfusion
- Chromosomal Abnormalities



EnBrace HR is proven in a 330 patient, randomized, controlled trial in patients with an MTHFR variant to lower homocysteine 30% compared to placebo group.

Andrew Farah, MD et al.  
Journal of Clinical Psychiatry, May 2016

# HOW TO PRESCRIBE

## STEP 1

### SUBMIT OUR ELECTRONIC FORM

Visit [www.enbracehrmf.com](http://www.enbracehrmf.com)

- Click "Clinician Prescribe"
- Fill out the required information
- Click "Submit."

## STEP 2

### INFORM YOUR PATIENT

Let your patient know that a friendly customer care representative will contact them shortly to get started on EnBrace HR for just \$1 a day for the first 60 days.

## STEP 3

### WE TAKE CARE OF THE REST

A representative will contact your patient to arrange the initial **60-day trial for just \$60**, which will typically be shipped the same day.

#### **REFILLS:**

Our Medical Food Distributor will handle all refills to ensure uninterrupted care.

# References

- 1.Freeman-et al., A prenatal supplement with methylfolate for the treatment and prevention of depression in women trying to conceive and during pregnancy, *Annals of Clinical Psychiatry*, Feb. 2019
- 2.Farah et.al, Correlation of Clinical Response with Homocysteine Reduction During Therapy With Reduced B Vitamins in Patients With MDD Who Are Positive for MTHFR C677T or A1298C Polymorphism, *Journal of Clinical Psychiatry*, May 2016
- 3.MRC Vitamin Group, Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study, *Lancet*, 1991
- 4.Czeizel et al., Periconceptional Folic Acid and Multivitamin Supplementation for the Prevention of Neural Tube Defects and Other Con-genital Abnormalities, *Clinical and Molecular Teratology*, 2008
- 5.FDA, 21 CFR-101.79- Health Claims: Folate and neural tube defects, CFR Text. 2019
- 6.Kirk E et al., Impact of the MTHFR C677T polymorphism on risk of neural tube defects: case-control study, *BMJ*, 2004
- 7.Ufriend et al., The C677T polymorphism of the methylenetetrahydrofolate reductase gene and idiopathic recurrent miscarriage, *Obstetrics & Gynecology*, April 2002
- 8.MTHFR Living, Preparing for Pregnancy with MTHFR Mutations, Jan. 2014
- 9.Garilli, Bianca ND, MTHFR Mutation: A Missing Piece in the Chronic Disease Puzzle, *Huffington Post*, Summer, 2012
10. Wald et al, Public health failure in the prevention of neural tube defects: time to abandon the tolerable upper intake level of folate,
- 11.Farah et al., The Prevalence and Role of MTHFR Polymorphism in Opiate Dependency, *Journal of Addiction and Therapies*, Feb. 2018
- 12.El-Hadidy et al., Methylene tetra hydrofolate reductase C677T Gene Polymorphism in Heroin Dependence, *Addiction Research & Therapy*, 2015
- 13.Mararwa et al., Prenatal exposure to SSRIs and SNRIs and risk for pulmonary hypertension of the newborn: a systemic review, meta-analysis, *AJOG*, 2018
- 14.Chambers et al., SSRI and Risk of Persistent Pulmonary Hypertension of the Newborn, *The New England Journal of Medicine*, 2011
- 15.Kieviet et al., Use of antidepressants during pregnancy in The Netherlands: observational study into post-partum interventions, *BMC Pregnancy & Childbirth*, 2017
- 16.MGH Center for Women's Health, [womensmentalhealth.org](http://womensmentalhealth.org), SSRIs and Poor Neonatal Adaptation: How Long do Symptoms Last, 2015
- 17.Liu et al., Antidepressant Use During Pregnancy and Psychiatric Disorders in Offspring, *BMJ*, 2017
- 18.Lugo-Candelas et al., Association Between Brain Structure and Connectivity in Infants and Exposure to SSRIs During Pregnancy, *JAMA Pediatrics*, 2018

# References cont'd

20. WebMD. [www.webmd.com](http://www.webmd.com), pregnancy-and-antidepressants, 2018
21. FDA A Appendix NIH, Antidepressant Drug Labels for Pregnant and Postpartum Women, 2014
22. EnBrace HR PI, FDS Daily Med, Dec. 2018
23. Turgal et al. MTHFR Polymorphisms and Pregnancy Outcome, PMC 6138472, Sept. 2018
24. Duprey Robert P. MTHFR Gene Polymorphism positive treatment-resistant depression, Neuropsychiatry 2019
25. Imbard A, Benoist JF, Blom HJ. Neural tube defects, folic acid and methylation. Int J Environ Res Public Health. 2013
26. Obeid R, Holzgreve W, Pietrzik K. Is 5-methyltetrahydrofolate an alternative to folic acid for the prevention of neural tube defects? J. Perinatal Med, 2013
27. Greenberg JA, Bell SJ, Guan Y, Yu YH. Folic Acid supplementation and pregnancy: more than just neural tube defect prevention. Rev Obstet Gynecol. 2011
28. NIH, Folate Fact Sheet for Professionals, 2022
29. MGH Center for Women's Mental Health, Folic Acid Supplements Before and After Conception: Prevention of Autism, 2022
30. Bjørk M, Riedel B, Spigset O, Veiby G, Kolstad E, Daltveit AK, Gilhus NE. Association of Folic Acid Supplementation During Pregnancy With the Risk of Autistic Traits in Children Exposed to Antiepileptic Drugs In Utero. JAMA Neurol. 2018 Feb
31. Sah AK, Shrestha N, Joshi P, Lakha R, Shrestha S, Sharma L, Chandra A, Singh N, Kc Y, Rijal B. Association of parental methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism in couples with unexplained recurrent pregnancy loss. BMC Res Notes. 2018 Apr
32. MGH Center for Women's Mental Health Folic Acid and Risk of Perinatal Depression: Is there an Association? 2012
33. Methylenetetrahydrofolate Reductase Polymorphisms and Pregnancy Outcomes, Obstetrics and Gynecology, 2018
34. Zhang L, Sun L, Wei T. Correlation between MTHFR gene polymorphism and homocysteine levels for prognosis in patients with pregnancy-induced hypertension. Am J Transl Res. 2021 Jul